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ABSTRACT
CONTEXT AND OBJECTIVE: Hypertensive urgencies are defined as severe elevations in blood pressure without evidence of acute or progressive target-organ 
damage. The need for treatment is considered urgent but allows for slow control using oral or sublingual drugs. If the increase in blood pressure is not 
associated with risk to life or acute target-organ damage, blood pressure control must be implemented slowly over 24 hours. For hypertensive urgencies, 
it is not known which class of antihypertensive drug provides the best results and there is controversy regarding when to use antihypertensive drugs and 
which ones to use in these situations. The aim of this review was to assess the effectiveness and safety of oral drugs for hypertensive urgencies. 
METHODS: This systematic review of the literature was developed at the Brazilian Cochrane Center, and in the Discipline of Emergency Medicine and 
Evidence-Based Medicine at the Universidade Federal de São Paulo — Escola Paulista de Medicina (Unifesp-EPM), in accordance with the methodology 
of the Cochrane Collaboration.
RESULTS: Sixteen randomized clinical trials including 769 participants were selected. They showed that angiotensin-converting enzyme inhibitors had a 
superior effect in treating hypertensive urgencies, evaluated among 223 participants. The commonest adverse event for calcium channel blockers were 
headache (35/206), flushing (17/172) and palpitations (14/189). For angiotensin-converting enzyme inhibitors, the principal side effect was bad taste 
(25/38). 
CONCLUSIONS: There is important evidence in favor of the use of angiotensin-converting enzyme inhibitors for treating hypertensive urgencies, compared 
with calcium channel blockers, considering the better effectiveness and the lower frequency of adverse effects (like headache and flushing).
RESUMO 
CONTEXTO E OBJETIVO: Urgências hipertensivas são definidas como elevações graves na pressão arterial sem evidência de danos agudos ou progressivos 
a órgãos-alvo. A necessidade de tratamento é considerada urgente, mas permite um controle gradual, utilizando-se drogas orais ou sublinguais. Se o 
aumento na pressão arterial não está associado a risco de vida ou danos a órgãos alvo, o controle pressórico deve ser feito lentamente durante 24 horas. 
Em relação às urgências hipertensivas, não é conhecida qual a classe de drogas anti-hipertensivas que promove os melhores resultados e há controvérsia 
em relação a quando e quais as drogas devem ser utilizadas nestas situações. O objetivo desta revisão foi avaliar a efetividade e a segurança de drogas 
orais para urgências hipertensivas. 
METODOS: Esta revisão sistemática da literatura foi desenvolvida no Centro Cochrane do Brasil, e na Disciplina de Medicina de Urgência e Medicina 
Baseada em Evidências da Universidade Federal de São Paulo — Escola Paulista de Medicina (Unifesp-EPM), de acordo com a metodologia da 
Colaboração Cochrane. 
RESULTADOS: Os 16 ensaios clínicos aleatórios selecionados incluíram 769 participantes e demonstraram um efeito superior dos inibidores da enzima 
conversora de angiotensina no tratamento da urgência hipertensiva, avaliada em 223 participantes. Os efeitos adversos mais frequentes para os 
bloqueadores de canal de cálcio foram cefaleia (35/206), rubor (17/172) e alterações do ritmo cardíaco (14/189); para os inibidores da enzima 
conversora de angiotensina, o efeito colateral mais frequente foi disgeusia (25/38). 
CONCLUSÕES: Há evidências importantes a favor do uso de inibidores da enzima conversora da angiotensina para o tratamento de urgências 
hipertensivas, quando comparados aos bloqueadores dos canais de cálcio, devido a maior efetividade e à menor frequência de efeitos adversos, como 
cefaléia e rubor facial.
KEY WORDS:  
Hypertension.  
Review [Publication Type]. 
Antihypertensive agents.  
Angiotensin-converting enzyme 
inhibitors.  
Calcium channel blockers.
PALAVRAS-CHAVE:  
Hipertensão.  
Revisão [tipo de publicação].  
Anti-hipertensivos.  
Inibidores da enzima conversora 
da angiotensina.  
Bloqueadores dos canais de 
cálcio.
Oral drugs for hypertensive urgencies:  systematic review and meta-analysis 
Sao Paulo Med J. 2009; 127(6):366-72 367
INTRODUCTION
Hypertensive crises have been divided into two categories: hyper-
tensive urgencies and hypertensive emergencies.1 Hypertensive urgen-
cies are defined as severe elevations in blood pressure (diastolic blood 
pressure above 120 mmHg) without evidence of acute, progressive tar-
get organ damage.2-5 The target organs are primarily the heart, brain, 
kidneys and large arteries. Hypertensive emergencies consist of elevated 
blood pressure (BP) with evidence of target organ dysfunction and have 
been the subject of a separate Cochrane review.6
Hypertension is common and affects about 50 million individuals 
in the United States and approximately one billion people worldwide.7 
In Brazil, cardiovascular diseases are responsible for more than 250,000 
deaths annually.7 Hypertensive urgencies are important clinical events 
occurring in both hospital and outpatient settings and comprise about 
76% of hypertensive crises.8 
In these situations, patients should be carefully evaluated with detailed 
history-taking and physical examination.9 The need for treatment is con-
sidered urgent but allows for slow control using oral or sublingual drugs.9 
As chronic hypertension results in a shift in cerebrovascular autoregula-
tion, in which blood pressure decreases too rapidly, to below the lower lim-
it of autoregulation, the brain may become hypoperfused, with symptoms 
such as dizziness, nausea and syncope.10 For this reason, if the increase in 
blood pressure is not associated with risk to life or acute target-organ dam-
age, blood pressure control must be implemented slowly over 24 hours.9 
Excessively rapid reductions in BP have been associated with acute deterio-
ration in renal function and ischemic cardiac or cerebral events.11 
Most patients with severe BP elevation can be managed on an out-
patient basis with oral agents and appropriate follow-up within 24 
hours to several days, depending on the individual characteristics of the 
patient.9 The initial goal for BP reduction is not to attain normal blood 
pressure but, rather, to achieve a progressive, controlled reduction in BP 
in order to minimize the risk of hypoperfusion in the cerebral, coronary 
and renovascular regions.10 
For hypertensive urgencies, it is not known which class of antihy-
pertensive drug provides the best results in terms of morbidity, mortal-
ity, blood pressure lowering efficacy, withdrawal due to adverse effects 
and other side effects. There is controversy regarding when to use blood 
pressure drugs and which ones to use in these situations, and the avail-
able evidence has been insufficient to answer these questions.
OBJECTIVE
To assess the effectiveness and safety of oral drugs for hypertensive 
urgencies.
MATERIALS AND METHODS
This systematic review of the literature was developed in accordance 
with the methodology of the Cochrane Collaboration and was conduct-
ed at the Brazilian Cochrane Centre, in the Universidade Federal de São 
Paulo — Escola Paulista de Medicina (Unifesp-EPM). It was approved 
by the local ethics committee.
The review only included randomized controlled clinical trials that 
evaluated the use of one or more drugs in the calcium channel blocker 
(CCB) or angiotensin-converting enzyme inhibitor (ACEi) groups. The 
participants in the trials had to meet all the criteria below:
- Diastolic blood pressure elevation to more than 110 mmHg and 
no evidence of acute target-organ damage.4 A lower pressure than 
in the current definition was used because we did not want to lose 
studies and because, prior to 1993, many cases of hypertensive ur-
gencies were defined and treated with diastolic blood pressures 
≥ 115 mmHg or ≥ 110 mmHg. 
- Age over 18 years.
- Patients with pregnancy-related and eclampsia-related hypertension 
were excluded.
- Patients with intractable nosebleed, sympathomimetic drug over-
dose, hypertension associated with increased circulating cate-
cholamines, end-stage organ damage (hypertensive emergencies), or 
other conditions requiring parenteral therapy were excluded.5
The outcomes evaluated were total mortality (from cardiovascu-
lar causes, from any cause or from side effects of the medication); any 
adverse effects reported in the studies included; proportion of patients 
with blood pressure decrease (for four-hour and 24-hour periods); pro-
portion of patients with target blood pressure of 140/90 mmHg; de-
crease in blood pressure in mmHg (for systolic blood and diastolic 
blood pressure); number of patients requiring addition of a second or 
third drug; incidence of hospitalization due to any cause; total non-fa-
tal cerebrovascular, cardiovascular and cardiopulmonary events (stroke, 
myocardial infarction, angina, silent ischemia, arrhythmias, congestive 
heart failure, kidney failure and acute pulmonary edema); and time tak-
en to achieve target BP.
Search strategy for identifying studies
The search strategy included the following databases: Medical Lit-
erature Analysis and Retrieval System Online (Medline) [1996 to Janu-
ary 2007]; Cochrane Systematic Review Database; Literatura Latino-
Americana e do Caribe em Ciências da Saúde (Lilacs) [1996 to January 
2007]; Excerpta Medica Database (Embase) [1996 to January 2007]; 
and specific websites (http://www.controlledtrials.com, http://clinical-
trials.gov/ct/gui, http://www.CenterWatch.com, http://scielo.br). Phar-
maceutical industry representatives, specialists in the field and the main 
authors of the trials included were contacted to obtain access to unpub-
lished data. There were no language restrictions. The terms used in the 
databases are available in Table 1.
Data extraction and methodological quality assessment
The search strategy identified the relevant articles. Each of these ar-
ticles was assessed by two independent reviewers. All the data were ex-
tracted by these two reviewers. Details relating to the population, treat-
ment periods and demographic baseline were extracted independently. 
A third reviewer was consulted to help in resolving disagreements. The 
quality of each trial was evaluated independently by the two reviewers, 
using the validated quality assessment tool that was published by Jadad 
et al. in 1996.12
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Table 1. Search strategies
Database Search strategy
Medline #1 (“Nifedipine”[Mesh]) OR (Procardia XL) OR (Adalat) OR (Bay-1040) OR (BAY-a-1040) OR (Cordipin) OR (Cordipine) OR (Corinfar) OR 
(Korinfar) OR (Fenigidin) OR (Infedipin) OR (Nifangin) OR (Nifedipine Monohydrochloride) OR (Monohydrochloride, Nifedipine) OR (Nifedipine-
GTIS) OR (Procardia) OR (nifedipine)
#2 (“Captopril”[MeSH]) OR ((S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline)) OR (Capoten) OR (Lopirin) OR (SQ-14,225) OR (SQ 
14,225) OR (SQ14,225) OR (SQ-14225) OR (SQ 14225) OR (SQ14225) OR (SQ-14,534) OR (SQ 14,534) OR (SQ14,534) OR (SQ-14534)
OR (SQ 14534) OR (SQ14534)
#3 (“Calcium Channel Blockers”[Mesh]) OR (Exogenous Calcium Antagonists) OR (Antagonists, Exogenous Calcium) OR (Calcium Antagonists, 
Exogenous) OR (Exogenous Calcium Blockaders) OR (Blockaders, Exogenous Calcium) OR (Calcium Inhibitors, Exogenous) OR (Calcium Chan-
nel Blocking Drugs) OR (Exogenous Calcium Inhibitors) OR (Inhibitors, Exogenous Calcium) OR (Calcium Blockaders, Exogenous) OR (Channel 
Blockers, Calcium) OR (Blockers, Calcium Channel) OR (Calcium Channel Blocker)
#4 (“Angiotensin-Converting Enzyme Inhibitors”[Mesh]) OR (Angiotensin Converting Enzyme Inhibitors)OR (Angiotensin-Converting Enzyme 
Antagonists) OR (Angiotensin Converting Enzyme Antagonists) OR (Enzyme Antagonists, Angiotensin-Converting) OR (Antagonists, Angiotensin-
Converting Enzyme) OR (Antagonists, Angiotensin Converting Enzyme) OR (Antagonists, Kininase II) OR (Inhibitors, Kininase II) OR (Inhibi-
tors, ACE) OR (ACE Inhibitors) OR (Kininase II Inhibitors) OR (Kininase II Antagonists) OR (Angiotensin I-Converting Enzyme Inhibitors) OR 
(Angiotensin I Converting Enzyme Inhibitors) OR (Inhibitors, Angiotensin-Converting Enzyme) OR (Enzyme Inhibitors, Angiotensin-Converting) 
OR (Inhibitors, Angiotensin Converting Enzyme)
#5 (hypertensive urgenc*) OR (“Hypertensive Encephalopathy”[Mesh]) OR (“Hypertension/complications” [MeSH]) OR (severe AND hyperten-
sion) OR (hypertensive AND crisis) OR (acute AND hypertens*) OR (acute AND treatment AND hypertension) OR (acute AND blood AND pres-
sure AND lowering AND effect) OR (malignant AND hypertension) OR (accelerat* AND hypertension) OR (hypertensive AND encephalopat*)
#6 #1 OR #2 OR #3 OR #4 AND #5
AND
(randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-
blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR (“clinical trial” [tw]) OR ((singl* [tw] OR 
doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR ( placebos [mh] OR placebo* [tw] OR random* [tw] OR 
research design [mh:noexp] OR comparative study [mh] OR evaluation studies [mh] OR follow-up studies [mh] OR prospective studies [mh] 
OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT humans [mh])
Cochrane Database #1 nifedipine
#2 captopril
#3 calcium channel blocker$
#4 angiotensin converting enzyme inhibitor$
#5 hypertensive urgenc$
Lilacs #1 (Nifedipine) or (Procardia XL) or (Adalat) or (Bay-1040) or (BAY-a-1040) or (Cordipin) or (Cordipine) or (Corinfar) or (Korinfar) or (Fenigi-
din) or (Infedipin) or (Nifangin) or (Nifedipine Monohydrochloride) or (Monohydrochloride, Nifedipine) or (Nifedipine-GTIS) or (Procardia) or 
(nifedipine)
#2 (Captopril) or ((S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline)) or (Capoten) or (Lopirin) or (SQ-14,225) or (SQ 14,225) or 
(SQ14,225) or (SQ-14225) or (SQ 14225) or (SQ14225) or (SQ-14,534) or (SQ 14,534) or (SQ14,534) or (SQ-14534) or (SQ 14534) or 
(SQ14534)
#3 (Calcium Channel Blockers) OR (Exogenous Calcium Antagonists) OR (Antagonists, Exogenous Calcium) OR (Calcium Antagonists, Exog-
enous) OR (Exogenous Calcium Blockaders) OR (Blockaders, Exogenous Calcium) OR (Calcium Inhibitors, Exogenous) OR (Calcium Channel 
Blocking Drugs) OR (Exogenous Calcium Inhibitors) OR (Inhibitors, Exogenous Calcium) OR (Calcium Blockaders, Exogenous) OR (Channel 
Blockers, Calcium) OR (Blockers, Calcium Channel) OR (Calcium Channel Blocker)
#4 (Angiotensin-Converting Enzyme Inhibitors) or (Angiotensin Converting Enzyme Inhibitors) or (Angiotensin-Converting Enzyme Antagonists) 
or (Angiotensin Converting Enzyme Antagonists) or (Enzyme Antagonists, Angiotensin-Converting) or (Antagonists, Angiotensin-Converting 
Enzyme) or (Antagonists, Angiotensin Converting Enzyme) or (Antagonists, Kininase II) or (Inhibitors, Kininase II) or (Inhibitors, ACE) or (ACE 
Inhibitors) or (Kininase II Inhibitors) or (Kininase II Antagonists) or (Angiotensin I-Converting Enzyme Inhibitors) or (Angiotensin I Converting 
Enzyme Inhibitors) or (Inhibitors, Angiotensin-Converting Enzyme) or (Enzyme Inhibitors, Angiotensin-Converting) or (Inhibitors, Angiotensin 
Converting Enzyme)
#5 #1 OR #2 OR #3 OR #4
#6 (hypertensive urgenc$) or (Hypertensive Encephalopathy) or (Hypertension/complications) OR (severe AND hypertension) OR (hypertensive 
AND crisis) OR (acute AND hypertens$) OR (acute AND treatment AND hypertension) OR (acute AND blood AND pressure AND lowering AND 
effect) OR (malignant AND hypertension) OR (accelerat$ AND hypertension) OR (hypertensive AND encephalopat$)
#7 ((Pt ENSAIO CONTROLADO ALEATORIO OR Pt ENSAIO CLINICO CONTROLADO OR Mh ENSAIOS CONTROLADOS ALEATORIOS OR Mh 
DISTRIBUICAO ALEATORIA OR Mh MÉTODO DUPLO-CEGO OR Mh MÉTODO SIMPLES-CEGO or PT ESTUDO MULTICENTRICO) or ((tw ensaio or tw 
ensayo or tw trial) and (tw azar or tw acaso or tw placebo or tw control$ or tw aleat$ or tw random$ or (tw duplo and tw cego) or (tw doble 
and tw ciego) or (tw double and tw blind)) and tw clinic$)) AND NOT ((Ct ANIMAIS OR ct coelhos or ct camundongos or MH ANIMAIS OR MH 
RATOS OR MH PRIMATAS OR MH CAES OR MH COELHOS OR MH SUINOS) AND NOT (Ct HUMANO AND Ct ANIMAIS))
#8 #5 AND #6 AND #7
Embase 1 ‘hypertensive crisis’/exp AND [humans]/lim
2 ‘hypertensive urgency’ AND [humans]/lim
3 #1 OR #2
4 ‘angiotensin receptor antagonist’/exp AND [humans]/lim
5 ‘captopril’/exp AND [humans]/lim
6 #4 OR #5
7 ‘calcium channel blocking agent’/exp AND [humans]/lim
8 ‘nifedipine’/exp AND [humans]/lim
9 #7 OR #8
10 #3 AND (#6 OR #7 OR #8) AND [humans]/lim
Medline = Medical Literature Analysis and Retrieval System Online; Lilacs = Literatura Latino-Americana e do Caribe em Ciências da Saúde; Embase = Excerpta Medica Database; MeSH = Medical Subject Headings. 
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Statistical analysis and presentation of the results
The statistical analysis was carried out using the ReviewManager 
program (version 5.0, RevMan, 2000), and in accordance with the Co-
chrane Collaboration Handbook.13 For dichotomous variables, the odds 
ratio (OR) method was used, with 95% confidence intervals (random 
effect model). When there was a statistical difference, the number need-
ed to treat (NNT) or the number needed to harm (NNH) was calculat-
ed. For continuous variables, the weighted mean difference was calculat-
ed (random effect model) with the corresponding 95% confidence in-
terval. If necessary, the original data were transformed into a logarithmic 
basis to obtain better distribution, or into scales that presented similar 
properties (the data on this scale would be the input for meta-analysis). 
Furthermore, if necessary, the continuous variables were subdivided for 
dichotomous analysis. To analyze the sensitivity, the following strategy 
using the Review Manager 5.0 software14 was proposed: 
a) Reanalysis of the data using reasonable variation of values for lost 
data: when dichotomous variables were extracted, it was assumed 
that participants lost from the experimental group presented unsuc-
cessful treatment and that losses from the control group presented 
improvement;
b) Reanalysis of the data using reasonable variation of the results from 
the studies, when there was some uncertainty in the results;
c) Reanalysis of the data using different statistical methods;
d) Statistical heterogeneity: it was planned that this would be evaluat-
ed in the studies by inspection of the graphical presentation (a dis-
persion graph in which the study weight or sample size was put on 
the y-axis, versus the risk ratio on the x-axis), and by the heterogene-
ity test (chi-squared test with n degrees of freedom, in which n was 
the number of studies that contributed data, minus one).13
RESULTS
Sixteen randomized controlled trials15-30 (769 patients) met the in-
clusion criteria for this review. We excluded 58 clinical trials for several 
reasons:
•	 One	randomized	controlled	trial	included	the	same	patients	as	in	a	
previous study.31 
•	 Twelve	 trials	mixed	patients	with	 and	without	 acute	 target-organ	
damage in the same randomized controlled trial.32-43
•	 Eighteen	 trials	 included	non-randomized	 participants	 in	 the	 trial	
results.44-61
•	 Five	trials	had	inadequate	randomization.62-66
•	 One	trial	did	not	report	any	of	the	outcomes	of	interest.67
•	 Five	trials	did	not	fulfill	the	blood	pressure	threshold	criteria.68-71
•	 Two	trials	did	not	fulfill	the	patient	threshold	criteria.72,73
•	 One	had	a	double-dummy	design.74
•	 Thirteen	 trials	 compared	 interventions	 that	 were	 not	 within	 the	
scope of this review.75-86
For the purposes of statistical analysis, the comparisons were made 
according to the outcomes, by comparing the following groups: 1) CCB 
versus ACEi; 2) placebo versus CCB; 3) placebo versus ACEi; 4) CCB 
versus other interventions; and 4) ACEi versus other interventions.
Outcomes
Total mortality: No trial reported total mortality.
Adverse effects: There were significant differences favoring partici-
pants receiving ACEi drugs, compared with CCB drugs, concerning ad-
verse effects such as flushing15,16,19,22,29 (risk ratio 0.22; 95% confidence 
interval 0.07 to 0.72) and headache16,19,22,28,29 (risk ratio 0.34; 95% con-
fidence interval 0.13 to 0.92) (Figures 1 and 2). 
Proportion of patients with blood pressure decrease: Only one 
study described this outcome as part of the results,30 and it showed that 
the proportion of blood pressure decrease over four hours was 92% for 
both groups (captopril and nifedipine).
Proportion of patients with target blood pressure of 140/90 
mmHg: No trial reported this outcome.
Number of patients requiring addition of a second or third drug: 
Four trials15,24,25,29 reported this outcome. Two patients in the CCB 
group and four patients in the control group (other drugs) required ad-
ministration of an additional drug.24 There were no significant differ-
ences favoring participants receiving ACEi drugs compared with CCB 
drugs, in relation to this outcome (Figure 3).15,25,29 
Incidence of hospitalization due to any cause: One trial29 reported 
that one patient needed hospitalization, and two cases of hospitaliza-
tion: one case due to treatment failure with CCB use and the other case 
due to treatment failure with ACEi drugs.
Total non-fatal cerebrovascular, cardiovascular and cardiopulmo-
nary events: One trial19 reported one patient with angina after taking 
CCB to treat hypertensive urgency.
Time taken to achieve target blood pressure: This was reported in 10 
trials.15-17,22-24,26,28-30 The results relating to this outcome were very variable, 
and meta-analysis could not be performed because of the absence of data 
to calculate the standard deviation and lack of definition of the desired 
target blood pressure. For the CCB group, the time needed for blood 
pressure reduction ranged from 30 minutes30 to 100 minutes.15 For the 
ACEi group, this time ranged from 30 minutes30 to 120 minutes.15,16
According to the Jadad Scale, the quality assessment was as follows: 
three trials received one point (described as randomized, inadequate ran-
domization, no double-blinding, no withdrawals description),17,27,28 four 
trials received two points (described as randomized, adequate random-
ization, no double-blinding and no withdrawals description),16,25,29,30 
six trials received three points (described as randomized, adequate ran-
domization, described as double-blinded, inadequate double-blinding 
and no withdrawals description)18-20,22,23,29 and three trials received four 
points (described as adequate randomization, adequate double-blind-
ing, no withdrawals description).15,21,26
DISCUSSION
This was the first systematic review investigating mortality and mor-
bidity outcomes among all randomized controlled trials (RCT) on drug 
treatments for hypertensive urgencies. The Cochrane Collaboration 
methodology was followed closely by conducting extensive literature 
search, followed by critical evaluation of RCT found. 
A previous systematic review that combined hypertensive emergen-
cies and urgencies did not include 11 trials that were included in our 
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ACE inhibitors CCB Risk Ratio Risk Ratio
Study or Sugroup Events Total Events Total Weight M-H, Random, 95% CI M-H, Random, 95% CI
Agurto Lescano et al.15 1 21 1 16 19.1% 0.76 [0.05, 11.27]
Dasmaceno et al.16 0 18 2 27 15.6% 0.29 [0.01, 5.80]
Gemici et al.19 0 46 5 34 16.9% 0.07 [0.00, 1.18]
Komsuoğlu et al.22 0 20 3 23 16.4% 0.16 [0.01, 2.98]
Pérez et al.29 1 27 5 27 32.0% 0.20 [0.02, 1.60]
Total (95% CI) 132 127 100.0% 0.22 [0.07, 0.72]
Total events 2 16
Heterogeneity: Tau2 = 0.00; Chi2 = 1.60, df = 4(P=0.81); I2 = 0% 0.005 0.1 1 10 200
Test for overral effect: Z = 2.52(P=0.01) Favors ACE inhibitors     Favors CCB
Figure 1. Forest plot for comparison between angiotensin-converting enzyme inhibitors and calcium channel blockers, in relation to the outcome of flushing.
ACE inhibitors CCB Risk Ratio Risk Ratio
Study or Sugroup Events Total Events Total Weight M-H, Random, 95% CI M-H, Random, 95% CI
Dasmaceno et al.16 0 18 7 27 12.6% 0.10 [0.01, 1.62]
Gemici et al.19 2 46 4 24 36.9% 0.37 [0.07, 1,90]
Komsuoğlu et al.22 0 20 6 23 12.5% 0.09 [0.01, 1.47]
Pascale et al.28 0 20 1 20 10.0% 0.33 [0.01, 7.72]
Pérez et al.29 2 27 2 27 27.9% 1.00 [0.15, 6.59]
Total (95% CI) 131 131 100.0% 0.34 [0.13, 0.92]
Total events 4 20
Heterogeneity: Tau2 = 0.00; Chi2 = 3.17, df = 4(P=0.53); I2 = 0% 0.005 0.1 1 10 200
Test for overral effect: Z = 2.12(P=0.03) Favors experimental     Favors control
Figure 2. Forest plot for comparison between angiotensin-converting enzyme inhibitors and calcium channel blockers, in relation to the outcome of headache
Figure 3. Forest plot for comparison between angiotensin-converting enzyme inhibitors and calcium channel blockers, in relation to the outcome of number 
of patients requiring addition of a second or third drug.
Review: Oral drus for hypertensive urgencies (April 2008)
Comparison: 03 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS X CALCIUM CHANNERL BLOCKERS
Outcome: 04 ADDITIONAL DRUG
Study ACEi CCB RR(random) Weight RR (random)
or sub-category n/N n/N 95% CI % 95% CI
Agurto Lescano et al.15 1/21 0/16 15.03 2.32 [0.10, 53.42]
Moritz et al.25 7/20 2/20 35.89 3.50 [0.83, 14.83]
Pérez et al.29 7/27 12/27 49.07 0.58 [0.27, 1.25]
Total (95% CI) 68 63 100.00 1.37 [0.33, 5.63]
Total events: 15 (ACEi), 14 (CCB)
Test for heterogeneity: Chi2 = 5.19, df = 2(P=0.07); I2 = 61.5%
Test for overall effect: Z = 0.43(P=0.67)
0.001 0.01 0.1 1 10 100 1000
Favors ACEi Favors CCB
systematic review and, furthermore, it mixed randomized with non-ran-
domized trials.3 The hypertensive urgencies included in that review had 
been treated with a variety of agents, and the main drugs used were cap-
topril (a type of ACEi) and nifedipine (a type of CCB). Perez’s review 
investigated mortality and morbidity outcomes among all randomized 
controlled trials on drug treatment for hypertensive emergencies.6 
The studies included in the present review had many limitations. 
First, there were large variations and inconsistencies in the definitions 
and cutoffs for urgencies and emergencies and for target blood pres-
sures. In 13 of the 58 trials excluded, patients with hypertensive urgen-
cies and emergencies were mixed or were not clearly discriminated in 
the same trial.75-86 If it had been possible to obtain the data on the indi-
vidual patients, the ones with hypertensive urgencies could have been 
added to our review. Second, there was a lack of definition regarding ur-
gencies and short-term trials. Third, important clinical outcomes were 
often not measured. Finally, the small numbers of patients (an average 
of 48 patients per trial) in the studies included limited their power to 
detect differences in mortality and morbidity. 
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CONCLUSIONS
Implications for practice
Evidence currently exists to suggest that the use of oral ACEi drugs 
for hypertensive urgencies produces better outcomes with regard to ef-
fectiveness and lower frequency of adverse effects, compared with CCB 
drugs. Thus, when possible, oral ACEi drugs should be used, except 
during pregnancy.
Implications for research  
Randomized controlled trials are needed to assess different blood pres-
sure lowering strategies and different drug classes in patients with hyper-
tensive urgencies. The outcomes measured in such trials should be the fol-
lowing: total mortality; any adverse effects reported; blood pressure reduc-
tion (proportion of patients with blood pressure decrease for four-hour and 
24-hour periods, and proportion of patients with target blood pressure of 
140/90 mmHg); systolic and diastolic blood pressure decrease (in mmHg); 
time taken to achieve target blood pressure; number of patients requiring 
additional drugs; incidence of hospitalization due to any cause; and total 
non-fatal cerebrovascular, cardiovascular and cardiopulmonary events, in-
cluding at least 24 hours of monitoring follow-up for all patients.
We believe that further collaborative, multicenter, randomized dou-
ble-blind controlled trials need to be performed in order to answer these 
questions more appropriately.
REFERENCES
1. Blumenfeld JD, Laragh JH. Management of hypertensive crises: the scientific basis for treat-
ment decisions. Am J Hypertens. 2001;14(11 Pt 1):1154-67. 
2. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Commit-
tee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 
report. JAMA. 2003;289(19):2560-72. 
3. Cherney D, Straus S. Management of patients with hypertensive urgencies and emergencies: 
a systematic review of the literature. J Gen Intern Med. 2002;17(12):937-45.
4. Varon J, Marik PE. The diagnosis and management of hypertensive crises. Chest. 
2000;118(1):214-27.
5. Abdelwahab W, Frishman W, Landau A. Management of hypertensive urgencies and emer-
gencies. J Clin Pharmacol. 1995;35(8):747-62. 
6. Perez MI, Musini VM. Pharmacological interventions for hypertensive emergencies. Cochrane 
Database Syst Rev. 2008;(1):CD003653.
7. Brasil. Ministério da Saúde. Saúde Brasil 2006: uma análise da desigualdade em saúde [Bra-
zilian health 2006: an analysis of health inequalities]. Brasília: Ministério da Saúde; 2006.
8. Zampaglione B, Pascale C, Marchisio M, Cavallo-Perin P. Hypertensive urgencies and emer-
gencies. Prevalence and clinical presentation. Hypertension. 1996;27(1):144-7.
9. Vidt DG. Emergency room management of hypertensive urgencies and emergencies. J Clin 
Hypertens (Greenwich). 2001;3(3):158-64.
10. Shayne PH, Pitts SR. Severely increased blood pressure in the emergency department. Ann 
Emerg Med. 2003;41(4):513-29. 
11. Rynn KO, Hughes FL, Faley B. An emergency department approach to drug treatment of 
hypertensive urgency and emergency. Journal of Pharmacy Practice. 2005;18(5):363-76. 
Available from: http://online.sagepub.com/cgi/searchresults?fulltext=drug±treatment±
of±hypertensive±urgency±and±emergency&src=hw&andorexactfulltext=and. Accessed in 
2009 (Nov 26).
12. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical 
trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
13. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 
4.2.6 [updated September 2006]. In: The Cochrane Library, Issue 4, 2006. Chichester: 
John Wiley & Sons Ltd. Available from: http://www.cochrane.org/resources/handbook/
Handbook4.2.6Sep2006.pdf. Accessed in 2009 (Nov 26).
14. Revman 5.0 Review Manager (RevMan) [Computer software]. Version 4.3.2 for Windows. 
Copenhagen: Nordic Cochrane Centre, Cochrane Collaboration, 2008. 
15. Agurto Lescano H, Sarmiento Rojas K, Romero Castro M, Moncada Cárcamo C. Compara-
ción entre captopril y nifedipina en el tratamiento de urgencias hipertensivas [Comparison 
between captopril and nifedipina in the treatment of hypertensive urgencies]. Bol Soc Peru 
Med Interna. 1997;10(2):60-5. 
16. Damasceno A, Ferreira B, Patel S, Sevene E, Polónia J. Efficacy of captopril and nifedipine in 
black and white patients with hypertensive crisis. J Hum Hypertens. 1997;11(8):471-6. 
17. Dondici Filho J, Gomes JC, Castro EG, Luz NS, Abzaid A. Redução aguda da pressão arterial: 
estudo comparativo entre nifedipina e clonidina [Acute reduction of blood pressure: com-
parative study between nifedipine and clonidine]. Arq Bras Cardiol. 1991;56(2):127-30. 
18. Flores Gonzalez J, Martinez Fernandez L, Martinez Garcia R, Fiterre Lancis I, Perez Caballero M. 
Clonidina y Nifedipina Oral en el Tratamiento de la Urgencia Hipertensiva [Oral clonidine and 
nifedipine in the treatment of hypertensive emergencies]. Rev Cuba Med. 1996;35(3):156-63. 
19. Gemici K, Karakoc Y, Ersoy A, Baran I, Güllülü S, Cordan J. A Comparison of Safety and Effi-
cacy of Sublingual Captopril with Sublingual Nifedipine in Hypertensive Crisis. Int J Angiol. 
1999;8(3):147-9. 
20. Gemici K, Baran I, Bakar M, Demircan C, Ozdemir B, Cordan J. Evaluation of the effect of the 
sublingually administered nifedipine and captopril via transcranial doppler ultrasonography 
during hypertensive crisis. Blood Press. 2003;12(1):46-8. 
21. Habib GB, Dunbar LM, Rodrigues R, Neale AC, Friday KJ. Evaluation of the efficacy and safety 
of oral nicardipine in treatment of urgent hypertension: a multicenter, randomized, double-
blind, parallel, placebo-controlled clinical trial. Am Heart J. 1995;129(5):917-23. 
22. Komsuoğlu B, Sengün B, Bayram A, Komsuoğlu SS. Treatment of hypertensive urgencies with 
oral nifedipine, nicardipine, and captopril. Angiology. 1991;42(6):447-54. 
23. Mansur Ade P, Ramires JA, Avakian SD, de Paula RS, Pileggi F. Efeito comparativo do diaze-
pam, nifedipina, propranolol e da associação nifedipina e propranolol, por via sublingual, 
em pacientes com crise hipertensiva [Comparison of the effects of diazepam, nifedipine, 
propranolol and a combination of nifedipine and propranolol, by sublingual administration, 
in patients with hypertensive crisis]. Arq Bras Cardiol. 1991;57(4):313-7. 
24. McDonald AJ, Yealy DM, Jacobson S. Oral labetalol versus oral nifedipine in hypertensive 
urgencies in the ED. Am J Emerg Med. 1993;11(5):460-3. 
25. Moritz RD, Queiroz LP, Pereira MR, Scotinni MA. Estudo comparativo do uso da nifedipina e 
do captopril em urgências hipertensivas [Comparative study of the use of nifedipine and 
captopril in hypertensive emergencies]. Arq Bras Cardiol. 1989;52(6):323-6. 
26. Olmedo Canchola VH, Rosas Heredia ML, Campos de la Vega G. Comparación de la eficacia 
entre captopril sublingual contra placebo en urgencias hipertensivas [Comparison of the 
efficiency between sublingual captopril vs placebo in hypertensive urgencies]. Med Interna 
Méx. 2000;16(6):303-7. 
27. Opie LH, Jennings A. Sublingual captopril versus nifedipine in hypertensive crises. Lancet. 
1985;2(8454):555. 
28. Pascale C, Zampaglione B, Marchisio M. Management of hypertensive crisis: nifedipine 
in comparison with captopril, clonidine, and furosemide. Current Therapeutic Research. 
1992;51(1):9-18. Available from: http://cat.inist.fr/?aModele=afficheN&cpsidt=520255
2. Accessed in 2009 (Nov 26).
29. Pérez CC, Dougnac LA, Alvarez ZM, et al. Captopril sublingual versus nifedipina para el 
tratamiento de la crisis hipertensiva [Sublingual captopril versus nifedipine in the treatment 
of hypertensive crisis]. Rev Méd Chile. 1991;119(4):402-5.
30. Pujadas R, Jané J, Fornós C, Gago MJ, de la Concepción N. Comparison of sublingual cap-
topril and nifedipine in hypertensive crises. Arch Intern Med. 1987;147(1):175-6. 
31. Pujadas R, Jané J, Gago MJ, Fornos C, Escrivá E, Roca N. Captopril versus Nifedipina sublingual 
en el tratamiento de las crisis hipertensivas. Anales de Medicina Interna. 1987;4(10):524-5. 
32. Biollaz J, Waeber B, Brunner HR. Hypertensive crisis treated with orally administered capto-
pril. Eur J Clin Pharmacol. 1983;25(2):145-9.
33. Cristodorescu R, Bartha P, Dragan S, Nicolin M. Tratamentul crizei hipertensive cu nifedipina 
în teren [The treatment of hypertensive crisis with nifedipine as the basis]. Rev Med Interna 
Neurol Psichiatr Neurochir Dermatovenerol Med Interna. 1989;41(6):529-38. 
34. Dadkar VN, Karnik ND, Izar M, et al. Sublingual nifedipine and captopril in hypertensive 
urgencies and emergencies. Indian Heart J. 1993;45(3):185-7. 
35. Facci Júnior C, Gonçalves LC, Dias SE, Gantois CR, Facci AM, Barbosa ET.. Captopril na crise 
hipertensiva [Captopril in hypertensive crises]. Arq Bras Cardiol. 1984;42(1):73-6. 
36. Hirschl MM, Seidler D, Müllner M, et al. Efficacy of different antihypertensive drugs in the 
emergency department. J Hum Hypertens. 1996;10(Suppl 3):S143-6. 
37. Karachalios GN, Chrisikos N, Kintziou H, Petrogiannopoulos K, Kehagioglou K. Treatment of hyper-
tensive crisis with sublingual captopril. Current Therapeutic Research. 1990;48(1):5-9. Available 
from: http://cat.inist.fr/?aModele=afficheN&cpsidt=19273721. Accessed in 2009 (Nov 26).
38. Koehler NR, Rabin M, Chatkin JM, et al. Nifedipina comprimido via sub-lingual na cri-
se hipertensiva [Sublingual tablet of nifedipine in hypertensive crisis]. Rev AMRIGS. 
1985;29(2):113-5. 
39. Peret Martínez JJ, Roca-Cusachs i Coll A, Monmany i Roca J, Nolla i Panadès J. [Use of 
sublingual nifedipine in the hypertensive crisis]. Med Clin (Barc). 1983;81(13):558-60. 
Sao Paulo Med J. 2009; 127(6):366-72
Souza LM, Riera R, Saconato H, Demathé A, Atallah AN
372
40. Santos RJ, Cavalcanti R, Oliveira CC, et al. Ensaio terapêutico nifedipina sub lingual na crise hiper-
tensiva [Therapeutic assay sublingual nifedipine in hypertensive crisis]. ECMAL. 1986;4(1):20-2. 
41. Sobrino J, Coca A, de la Sierra A, Closas J, Aguilera MT, Urbano-Márquez A. Prevalencia, 
formas clínicas de presentación y tratamiento de la hipertensión arterial en una unidad de 
urgencias [Prevalence, forms of clinical presentation and treatment of arterial hypertension 
at an emergency unit]. Rev Clin Esp. 1990;187(2):56-60. 
42. Späh F, Grosser KD. Treatment of hypertensive urgencies and emergencies with nitrendipine, 
nifedipine, and clonidine: effect on blood pressure and heart rate. J Cardiovasc Pharmacol. 
1988;12(Suppl 4):S154-6. 
43. Tereshchenko SN, Dzhaiani NA, Morozova MN. [Comparative efficacy of carvedilol and capo-
ten in the treatment of an uncomplicated hypertensive crisis]. Ter Arkh. 2006;78(8):26-30. 
44. Alletto M, Burgio A, Fulco G, Paradiso R, Piangiamore M, Vancheri F. Captopril sublingua-
le nelle crisi ipertensive [Sublingual captopril in hypertensive crises]. Recenti Prog Med. 
1992;83(9):503-5. 
45. Castro del Castillo A, Rodriguez M, Gonzalez E, Rodriguez F, Estruch J. Dose-response effect 
of sublingual captopril in hypertensive crises. J Clin Pharmacol. 1988;28(7):667-70. 
46. Domínguez B, Díaz R. Tratamiento de las urgencias y de las crises hipertensivas con nifedipi-
na sublingual [Treatment of hypertensive emergencies and crisis with sublingual nifedipine]. 
Rev Med Panama. 1988;13(2):100-6. 
47. Gómez Santos FA, Hidalgo Nuñez LW, Mendoza de Jesús A, Sanz MA, Noyer J. Nifedipina 
sublingual en el manejo de la crisis hipertensiva [Sublingual nifedipine in hypertensive 
emergency]. Rev Méd Domin. 1992;53(1):25-7. 
48. Gökel Y, Paydas S, Kuvandik G, Alparslan N. Sublingual valsartan in hypertensive urgency. Turkish 
Journal of Medical Sciences. 2001;31(6):565-7. Available from: http://journals.tubitak.gov.tr/
medical/issues/sag-01-31-6/sag-31-6-17-0101-13.pdf. Accessed in 2009 (Nov 26). 
49. Guazzi M, Olivari MT, Polese A, Fiorentini C, Magrini F, Moruzzi P. Nifedipine, a new antihyper-
tensive with rapid action. Clin Pharmacol Ther. 1977;22(5 Pt 1):528-32. 
50. Heller MB, Duda J, Maha RJ, et al. Prehospital use of nifedipine for severe hypertension. Am 
J Emerg Med. 1990;8(4):282-4. 
51. Hirschl MM, Seidler D, Zeiner A, et al. Intravenous urapidil versus sublingual nifedipine in the 
treatment of hypertensive urgencies. Am J Emerg Med. 1993;11(6):653-6. 
52. Karnik ND, Bhatt AD, Trivedi TH, et al. Nifedipine, captopril, metoprolol and nifedipine with 
metoprolol in hypertensive crisis in non-intensive care setting. J Assoc Physicians India. 
1996;44(7):480-2. 
53. Maciel R, Spritzer N, Spritzer TS, Abichequer MH. Captopril na crise hipertensiva [Captopril 
in the hypertensive crisis]. Arq Bras Cardiol. 1983;40(6):429-31. 
54. Martínez-Amenós A, Carratalà J, Pintó X, Santaló M, Tamayo C, Pujol M. [Hypertensive crisis: 
comparative study of oral captopril, sublingual captopril and sublingual nifedipine]. Med 
Clin (Barc). 1987;89(2):59-61. 
55. Pose Reino A, González-Juanatey JR, Fernández Velo JL, Amaro Cendón A, Bugallo Paz L, Gil 
de la Peña M. Enalapril sublingual en crisis hipertensiva. Estudio preliminar [Sublingual 
enalapril in hypertensive crisis. A preliminary study]. An Med Interna. 1989;6(8):421-3. 
56. Preston RA, Baltodano NM, Cienki J, Materson BJ. Clinical presentation and management of 
patients with uncontrolled, severe hypertension: results from a public teaching hospital. J 
Hum Hypertens. 1999;13(4):249-55. 
57. Rubio Guerra AF, Vargas Ayala G, Rodrígues López L, Lozano Nuevo JJ, Trejo Orozco N. Com-
paración entre nifedipina sublingual y dosis sucesivas de dinitrato de isosorbide en aerosol 
para las crises hipertensivas [Sub-lingual nifedipine vs. isosorbide spray in hypertensive 
crisis]. Rev Fac Med UNAM. 1999;42(4):148-50. 
58. Saragoça MA, Ribeiro AB, Ramos OL. Crise hipertensiva. Tratamento com captopril após 
insucesso com diurético. Estudo multicêntrico [Hypertensive crisis. Treatment with captopril 
after failure with diuretic. Multicentric study]. Arq Bras Cardiol. 1982;38(5):415-9. 
59. Sulbarán T, Aparicio J, Bermúdez G. Uso del captopril sublingual en crisis hipertensivas [The 
use of sublingual captopril in hypertensive crises]. Invest Clin. 1994;35(3):143-54. 
60. Toledo Hviid GE, Justiniano Encina J. Captopril sublingual en las crisis Hipertensivas [Sublin-
gual captopril in hypertensive crisis]. Rev Méd Cruceña. 1995;(15):40-3. 
61. Wyss F, Ovando A, Loria R. Captopril sublingual en urgencia hipertensiva [Sublingual capto-
pril in hypertensive emergencies]. Rev Med Interna. 1999;10(2):16-8. 
62. Franklin C, Nightingale S, Mamdani B. A randomized comparison of nifedipine and sodium 
nitroprusside in severe hypertension. Chest. 1986;90(4):500-3. 
63. Isles CG, Johnson AO, Milne FJ. Slow release nifedipine and atenolol as initial treatment in 
blacks with malignant hypertension. Br J Clin Pharmacol. 1986;21(4):377-83. 
64. Just VL, Schrader BJ, Paloucek FP, Hoon TJ, Leikin JB, Bauman JL. Evaluation of drug therapy 
for treatment of hypertensive urgencies in the emergency department. Am J Emerg Med. 
1991;9(2):107-11. 
65. Lima SG, Nascimento LS, Santos Filho CN, Albuquerque MFPM, Victor EG. Hipertensão ar-
terial sistêmica no setor de emergência: o uso de medicamentos sintomáticos como alter-
nativa de tratamento [Systemic hypertension at emergency units: the use of symptomatic 
drugs as choice for management]. Arq Bras Cardiol. 2005;85(2):115-23. 
66. Misra A, Jain P, Reddy RB. Sublingual captopril in hypertensive urgencies. Postgrad Med J. 
1993;69(812):498-9. 
67. Sol JB, Gonzáles RR, Planas JT, Riera AC. El tratamiento hipotensor sublingual. ¿Compara 
grupos homogêneos de hipertensos? Revista Clinica Española. 1987;181(7):403-4. 
68. Bussmann WD, Kenedi P, von Mengden HJ, Nast HP, Rachor N. Comparison of nitroglycerin 
with nifedipine in patients with hypertensive crisis or severe hypertension. Clin Investig. 
1992;70(12):1085-8. 
69. Diker E, Ertürk S, Akgün G. Is sublingual nifedipine administration superior to oral adminis-
tration in the active treatment of hypertension? Angiology. 1992;43(6):477-81. 
70. Gökel Y, Satar S, Paydas S. A comparison of the effectiveness of sublingual losartan, sublin-
gual captopril and sublingual nifedipine in hypertensive urgency. Turkish Journal of Medical 
Sciences. 1999;29(6):655-60. Available from: http://journals.tubitak.gov.tr/medical/
issues/sag-99-29-6/sag-29-6-11-98183.pdf. Accessed in 2009 (Nov 26).
71. Bussmann WD, Kenedi P, von Mengden HJ, Nast HP, Rachor M. Nitroglycerin im Vergleich zu 
Nifedipin bei Patienten mit hypertensiver Krise [Nitroglycerin in comparison with nifedipine 
in patients with hypertensive crisis]. Z Kardiol. 1993;82(1):33-7. 
72. Vázquez Vigoa A, Gundián González-Piñera J, Cordiés Jackson L, Pérez Caballero MD. Captopril 
versus nifedipina sublingual en el tratamiento de la urgencia hipertensiva [Captopril versus nifedi-
pine given sublingually in treating hypertensive emergency]. Rev Cuba Med. 1993;32(1):19-27. 
73. Sechi LA, Tedde R, Cassisa L, et al. Sublingual and intravenous ketanserin versus sublingual nifedi-
pine in the treatment of severe hypertension: a randomized study. Clin Ther. 1989;11(6):834-40. 
74. Woisetschläger C, Bur A, Vlcek M, Derhaschnig U, Laggner AN, Hirschl MM. Comparison 
of intravenous urapidil and oral captopril in patients with hypertensive urgencies. J Hum 
Hypertens. 2006;20(9):707-9. 
75. Al-Waili NS, Hasan NA. Efficacy of sublingual verapamil in patients with severe essential 
hypertension: comparison with sublingual nifedipine. Eur J Med Res. 1999;4(5):193-8. 
76. Damasceno A, Sevene E, Patel S, Polónia J. Nifedipine-retard versus nifedipine-capsules for the 
therapy of hypertensive crisis in black patients. J Cardiovasc Pharmacol. 1998;31(1):165-9. 
77. Dessì-Fulgheri P, Bandiera F, Rubattu S, et al. Comparison of sublingual and oral captopril in 
hypertension. Clin Exp Hypertens A. 1987;9(2-3):593-7. 
78. Guazzi MD, De Cesare N, Galli C, Salvioni A, Tamborini G, Tosi E. La nifédipine en tant 
qu’antihypertenseur vasodilatateur d’effet rapide [Nifedipine as a vasodilator antihyperten-
sive with a rapid action]. Arch Mal Coeur Vaiss. 1985;78 Spec No:59-65. 
79. Maharaj B, van der Byl K. A comparison of the acute hypotensive effects of two different 
doses of nifedipine. Am Heart J. 1992;124(3):720-5. 
80. Phillips RA. Hypertensive urgencies. Emergency Medicine 1990;15:91-100. 
81. Sánchez M, Sobrino J, Ribera L, Adrián MJ, Torres M, Coca A. Long-acting lacidipine versus 
short-acting nifedipine in the treatment of asymptomatic acute blood pressure increase. J 
Cardiovasc Pharmacol. 1999;33(3):479-84. 
83. Saragoça MA, Portela JE, Plavnik F, Ventura RP, Lotaif L, Ramos OL. Isradipine in the treatment 
of hypertensive crisis in ambulatory patients. J Cardiovasc Pharmacol. 1992;19 Suppl 3: 
S76-8. 
84. Savi L, Montebelli MR, D’Alonzo S, Mettimano M, Folli G. Sublingual nicardipine versus nife-
dipine to treat hypertensive urgencies. Int J Clin Pharmacol Ther Toxicol. 1992;30(2):41-5. 
85. Schneider E, Jennings AA, Opie LH. Captopril, nifedipine and their combination for the-
rapy of hypertensive urgencies. Survey of Anestesiology. 1992;36(4):247. Available from: 
http://journals.lww.com/surveyanesthesiology/Citation/1992/06000/Captopril,_Nifedi-
pine_and_Their_Combination_for.42.aspx. Accessed in 2009 (Nov 26).
86. Veloz M. Captopril oral versus sublingual en crisis hipertensivas [Oral Captopril versus su-
blingual in hypertensive crises]. Quito; s.n; s.f. 16 p. graf, tab. 
87. Zampaglione B, Pascale C, Marchisio M, Santoro A. The use of lacidipine in the management 
of hypertensive crises: a comparative study with nifedipine. J Cardiovascular Pharmacol. 
1994;23 Suppl 5:S116-8.
Sources of funding: Not declared
Conflict of interest: None
Date of first submission: October 5, 2009
Last received: December 8, 2009
Accepted: December 10, 2009 
Address for correspondence:  
Rachel Riera 
Centro Cochrane do Brasil 
Rua Pedro de Toledo, 598  
Vila Clementino — São Paulo (SP) — Brasil 
CEP 04039-001 
Tel./Fax. (±55 11) 5575-2970/5579-0469 
E-mail: rachelriera@hotmail.com
